Jane Street’s Vaxcyte PCVX Stock Holding History

Jane Street’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.3M	Buy	573,200 +544,900	+1,925%	+$29.6M	﹤0.01%	1342
2025 Q4	$1.31M	Buy	28,300 +16,000	+130%	+$716K	﹤0.01%	5598
2025 Q3	$443K	Buy	+12,300	New	+$408K	﹤0.01%	8114
2025 Q2	–	Sell	-8,500	Closed	-$321K	–	10535
2025 Q1	$321K	Sell	8,500 -4,000	-32%	-$320K	﹤0.01%	7690
2024 Q4	$1.02M	Sell	12,500 -9,100	-42%	-$904K	﹤0.01%	5346
2024 Q3	$2.47M	Buy	21,600 +8,600	+66%	+$775K	﹤0.01%	4048
2024 Q2	$982K	Sell	13,000 -3,800	-23%	-$259K	﹤0.01%	5812
2024 Q1	$1.15M	Buy	+16,800	New	+$1.16M	﹤0.01%	5146
2023 Q3	–	Sell	-56,100	Closed	-$2.8M	–	9180
2023 Q2	$2.8M	Buy	+56,100	New	+$2.66M	﹤0.01%	3621

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's PCVX Position: Q1 2026 in Review

Jane Street reduced its Vaxcyte (PCVX) stake by 9.6% in Q1 2026, selling an estimated $1.45M and leaving 252,877 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Jane Street first reported a position in PCVX in Q2 2020 and has held it in 15 quarters since. The position peaked at $24.5M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Jane Street held 252,877 shares of Vaxcyte worth $14.7M as of Q1 2026.
Jane Street sold 26,727 Vaxcyte shares in Q1 2026, an estimated $1.45M.
Vaxcyte made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2084 holding.
Jane Street first reported a position in Vaxcyte in Q2 2020 and has held it in 15 quarters since.
Jane Street's Vaxcyte position peaked at $24.5M in Q4 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.